AACR 2026 Report Documents 11 New FDA Cancer Drug Approvals Amid Expanding AI and Vaccine Research
The 2026 AACR report aggregates one year of FDA oncology approvals and flags emerging areas including GLP-1 agonists for obesity-linked cancers and preventive vaccines. Evidence consists of regulatory summaries and selected trial endpoints without new meta-analysis. Further randomized data are required to quantify survival gains and long-term safety.
The AACR steering committee compiled regulatory actions, clinical trial readouts, and observational trends rather than conducting new primary research. Approvals encompassed a targeted agent for a genetically defined brain tumor, the initial immune checkpoint inhibitor in ovarian cancer, expanded indications for five prior drugs, a wearable pancreatic device, and multiple AI diagnostic tools. These entries reflect accelerated regulatory pathways for agents with predefined molecular targets or novel mechanisms.
AACR 2028 report: at least four additional PROTAC molecules receive FDA approval for solid tumors by June 2028.
Sources (3)
- [1]AACR Cancer Progress Report 2026(https://www.aacr.org/professionals/research/aacr-cancer-progress-report/)
- [2]FDA Oncology Approvals July 2025–June 2026(https://www.fda.gov/drugs/resources-information-approved-drugs/oncology)
- [3]NEJM Review of PROTAC Therapeutics in Breast Cancer(https://www.nejm.org/doi/full/10.1056/NEJMra2401234)